Management Board of MorphoSys AG

12
THE COMPANY
Management Board of MorphoSys AG
Management Board
of MorphoSys AG
DR. SIMON MORONE Y
Chief Executive Officer
THE COMPANY
Management Board of MorphoSys AG
» Excellent progress over the last
year means that today our pipeline
is broader and more mature than
ever before. The first therapeutic
antibodies are nearing market
­approval, bringing us closer to a
product-based revenue stream.
Meanwhile, our proprietary develop­
ment portfolio is expanding and
the two most advanced programs
are approaching decisive stages
of clinical development. Across our
entire pipeline, we see many pro­
grams with outstanding therapeu­
tic potential, to the benefit of all
of our stakeholders, not least the
patients who they will help. «
JENS HOL S T EIN Finanzvorstand
Letter to the Shareholders
13
12
THE COMPANY
Management Board of MorphoSys AG
Management
» With
Board
financial resources of close
of MorphoSys
to EUR
AG 300 million at year-end
2015, MorphoSys continues to
­operate from a position of
strength. Our solid financial base
has been the foundation for
­MorphoSys’s successful develop­
ment over the years, allowing
us to continue making targeted
­investments and grow the Com­
pany’s value without losing sight
of our prudent and efficient use
of resources. «
DR. SIMON MORONE Y
Vorstandsvorsitzender
THE COMPANY
Management Board of MorphoSys AG
JENS HOL S T EIN Chief Financial Officer
13
14
THE COMPANY
Management Board of MorphoSys AG
DR. MARL IE S SPROL L Chief Scientific Officer
THE COMPANY
Management Board of MorphoSys AG
» During 2015, our product pipeline
became broader and more mature
than ever before. Our partnered
programs are on the cusp of reap­
ing the first rewards of our long­
time efforts. In 2016, Novartis’s
bimagrumab and Janssen’s gusel­
kumab will be the first HuCAL anti­
bodies to deliver phase 3 data, and
we may see the first MorphoSys
antibody reach the market before
year-end – another exciting year
is lying ahead. «
DR. ARND T S C HO T T EL IUS Chief Development Officer
15
14
THE COMPANY
Management Board of MorphoSys AG
» In 2015 we generated encouraging
clinical data with our proprietary
cancer agents. We are now expand­
ing these programs and moving
them, step-by-step, towards ap­
proval and commercial viability.
At the center of this campaign will
be the start of three combination
studies with our most advanced
antibody MOR208 in DLBCL and CLL
in 2016, one of which is expected
to progress directly into a pivotal
study next year, marking yet an­
other major milestone in the history
of MorphoSys. «
DR. MARL IE S SPROL L Chief Scientific Officer
THE COMPANY
Management Board of MorphoSys AG
DR. ARND T S C HO T T EL IUS Chief Development Officer
15